Soumit Roy
Stock Analyst at Jones Trading
(3.05)
# 1,556
Out of 5,182 analysts
45
Total ratings
34.29%
Success rate
18.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Upgrades: Buy | $8 | $2.89 | +176.82% | 2 | Mar 10, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Buy | $7 | $4.16 | +68.27% | 1 | Dec 22, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $7 | $2.34 | +199.15% | 1 | Dec 22, 2025 | |
| EVAX Evaxion | Initiates: Buy | $10 | $4.18 | +139.23% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $3.29 | - | 1 | Oct 24, 2025 | |
| ATYR aTyr Pharma | Downgrades: Hold | n/a | $0.79 | - | 2 | Sep 15, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $66.82 | -25.17% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $4.99 | +320.84% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $30.33 | +31.88% | 1 | May 20, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Buy | $36 → $27 | $44.90 | -39.87% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.88 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.97 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $3.82 | +292.67% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.56 | +119.30% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $29.17 | +16.58% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.56 | +2,207.69% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $4.99 | +541.28% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $11.36 | -20.77% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $10.19 | +66.83% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $64 | $7.93 | +707.06% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.96 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $13.25 | +96.23% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $15.23 | +359.62% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $54.02 | -81.49% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.30 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | - | - | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.89 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $0.44 | +72,792.94% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $7.03 | +11,422.05% | 1 | Feb 24, 2021 |
Editas Medicine
Mar 10, 2026
Upgrades: Buy
Price Target: $8
Current: $2.89
Upside: +176.82%
Whitehawk Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $4.16
Upside: +68.27%
Context Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $2.34
Upside: +199.15%
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.18
Upside: +139.23%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.29
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.79
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $66.82
Upside: -25.17%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $4.99
Upside: +320.84%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $30.33
Upside: +31.88%
Enliven Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $44.90
Upside: -39.87%
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.88
Upside: -
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.97
Upside: -
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $3.82
Upside: +292.67%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $4.56
Upside: +119.30%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $29.17
Upside: +16.58%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.56
Upside: +2,207.69%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $4.99
Upside: +541.28%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $11.36
Upside: -20.77%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $10.19
Upside: +66.83%
Sep 11, 2024
Maintains: Buy
Price Target: $96 → $64
Current: $7.93
Upside: +707.06%
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.96
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $13.25
Upside: +96.23%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $15.23
Upside: +359.62%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $54.02
Upside: -81.49%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.30
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: -
Upside: -
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.89
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $0.44
Upside: +72,792.94%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $7.03
Upside: +11,422.05%